Windtree Therapeutics (WINT)
(Real Time Quote from BATS)
$10.02 USD
-1.78 (-15.09%)
Updated Aug 13, 2024 01:50 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
WINT 10.02 -1.78(-15.09%)
Will WINT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for WINT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WINT
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
WINT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for WINT
(WINT) - Analyzing Windtree Therapeutics's Short Interest
Windtree Therapeutics Inc trading resumes
Windtree Therapeutics Inc trading halted, volatility trading pause
Windtree Therapeutics Inc trading resumes
Windtree Therapeutics Inc trading halted, volatility trading pause